INT71069

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.03
First Reported 1997
Last Reported 1997
Negated 2
Speculated 0
Reported most in Abstract
Documents 1
Total Number 2
Disease Relevance 0.13
Pain Relevance 3.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (Tac4) plasma membrane (Oprl1) signal transducer activity (Oprl1)
Anatomy Link Frequency
ventromedial hypothalamic nucleus 4
Oprl1 (Rattus norvegicus)
Tac4 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Cholecystokinin 24 100.00 Very High Very High Very High
opiate 16 100.00 Very High Very High Very High
antagonist 8 100.00 Very High Very High Very High
amygdala 6 99.36 Very High Very High Very High
Limbic system 6 79.84 Quite High
Neuropeptide 4 78.24 Quite High
Enkephalin 8 75.00 Quite High
substance P 8 73.04 Quite High
Endogenous opioid 8 70.24 Quite High
Central grey 2 65.72 Quite High
Disease Link Frequency Relevance Heat
Urological Neuroanatomy 2 65.72 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The universal opiate receptor antagonist naltrexone and the delta-opiate receptor antagonist naltrindole each potentiated the estrogen-induced increase and elevated cholecystokinin messenger RNA levels an additional 1.9- to 2.8-fold depending on the nucleus examined, but had no effect on the estrogen-induced expression of either preproenkephalin or preprotachykinin messenger RNA. beta-Funaltrexamine, a mu-opiate receptor antagonist, had no effect on the medial preoptic or medial amygdaloid cholecystokinin messenger RNA levels or on the estrogen-induced expression of preproenkephalin messenger RNA but did cause a decrease in estrogen-induced cholecystokinin messenger RNA levels in the bed nucleus of the stria terminalis and a decrease in the preprotachykinin messenger RNA levels in the ventromedial hypothalamic nucleus.
opiate receptor Neg (no) Regulation (effect) of Gene_expression (expression) of preprotachykinin in ventromedial hypothalamic nucleus associated with antagonist, opiate and cholecystokinin
1) Confidence 0.03 Published 1997 Journal Neuroscience Section Abstract Doc Link 9284350 Disease Relevance 0.07 Pain Relevance 1.83
The universal opiate receptor antagonist naltrexone and the delta-opiate receptor antagonist naltrindole each potentiated the estrogen-induced increase and elevated cholecystokinin messenger RNA levels an additional 1.9- to 2.8-fold depending on the nucleus examined, but had no effect on the estrogen-induced expression of either preproenkephalin or preprotachykinin messenger RNA. beta-Funaltrexamine, a mu-opiate receptor antagonist, had no effect on the medial preoptic or medial amygdaloid cholecystokinin messenger RNA levels or on the estrogen-induced expression of preproenkephalin messenger RNA but did cause a decrease in estrogen-induced cholecystokinin messenger RNA levels in the bed nucleus of the stria terminalis and a decrease in the preprotachykinin messenger RNA levels in the ventromedial hypothalamic nucleus.
delta-opiate receptor Neg (no) Regulation (effect) of Gene_expression (expression) of preprotachykinin in ventromedial hypothalamic nucleus associated with antagonist, opiate and cholecystokinin
2) Confidence 0.03 Published 1997 Journal Neuroscience Section Abstract Doc Link 9284350 Disease Relevance 0.06 Pain Relevance 1.81

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox